EDGAR·FLOW

Freenome, Inc. — Form 8-K

Filed November 10, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
Freenome completed IPO on July 21, 2026, raising ~$310M gross proceeds, and received FDA approval for SimpleScreen CRC colorectal cancer test on July 24, 2026. Q3 2026 revenue surged to $183.5M (vs. $1.0M in Q3 2025), driven by $182.5M license/collaboration revenue from Abbott (assumed Exact Sciences agreement); $100M milestone payment triggered by FDA approval. Company holds $430M in cash/securities as of Sept 30, 2026; converted ~$50.5M Abbott convertible note into 3.4M shares at $15/share and ~$6.4M Roche convertible note into 6.4M shares at $12/share upon July business combination close.
Why this rating

IPO capital ($310M) and milestone payment ($100M) represent 4.5x and 1.1x company market cap, respectively. FDA approval and commercial launch de-risk product viability. Revenue 177x YoY growth; positive GAAP net income Q3 vs. prior losses. Material for company scale but execution risk remains on adoption and pipeline advancement.

Tradability signal
SHORT conviction 19/100 · expected -0.41% over 4 hrs

SHORT (fade the pop): stock already ran +5.2% on this news, and positive calls in this cell have historically given the pop back (-0.43% over 4 hrs, n=441). Reversion play, lower conviction by design. Exit plan: HARD stop 7.7% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$10.69 ▼ 2.99%
at our read · unknown
$11.02
+10 min · unknown
$11.32 ▲ 2.72%
+30 min · unknown
$11.22 ▲ 1.86%
+1 hr · unknown
$10.99 ▼ 0.27%
+4 hrs · unknown
$11.26 ▲ 2.18%

The stock had already moved +3.09% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ FRNM · stock on Yahoo Finance ↗

See more from November 10, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.